Evidence map›Paper›PMID 36552236›Full record

ArticleBiology2022

The Activity of Polyhomoarginine against

Hari Kumar Peguda, Rajamani Lakshminarayanan, Nicole A Carnt, Zi Gu, Mark D P Willcox

Erratum issuedAbstract read
In one paragraph

Article in Biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Complicated Diagnosis and Treatment of Rare PainlessJournal of clinical medicine · 2025
    Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Hari Kumar PegudaSchool of Optometry and Vision Science, University of New South Wales, Sydney 2052, Australia.ORCID 0000-0002-1317-5040
Rajamani LakshminarayananOcular Infections and Anti-Microbials Research Group, Singapore Eye Research Institute, Singapore 169856, Singapore.ORCID 0000-0001-8214-5315
Nicole A CarntSchool of Optometry and Vision Science, University of New South Wales, Sydney 2052, Australia.
Zi GuSchool of Chemical Engineering, University of New South Wales, Sydney 2052, Australia.ORCID 0000-0002-7153-6596
Mark D P WillcoxSchool of Optometry and Vision Science, University of New South Wales, Sydney 2052, Australia.ORCID 0000-0003-3842-7563

Funding

Singapore Ministry of Health's National Medical Research Council under its Centre Grant Programme and Open Funding - Independent Research Grant MOH-001001-00 and MOH-000963-00
6 · The paper itself

Abstract

Arginine-rich peptides can have broad-spectrum anti-bacterial and anti-fungal activities. Polyhomoarginine consists of highly cationic residues which can act on the negatively charged microbial cell membranes. Acanthamoeba is a free-living protozoan known to cause a rare corneal infection which is difficult to diagnose and treat. This study evaluated the activity of the polyhomoarginines against Acanthamoeba castellanii. Acanthamoeba amoebicidal, amoebistatic, encystation and excystment assays were performed using protocols described in the literature. The activity of polyhomoarginines (PHAs) of different lengths (10 to 400 residues) was measured against the trophozoites and cysts of Acanthamoeba castellanii ATCC30868 in concentrations ranging from 0.93 μM to 15 μM. Data were represented as mean ± SE and analysed using one-way ANOVA. Overall, PHAs demonstrated good anti-acanthamoeba activity against both trophozoites and cysts. PHA 30 reduced the number of viable trophozoites by 99%, inhibited the formation of cysts by 96% and the emergence of trophozoites from cysts by 67% at 3.75 μM. PHA 10 was similarly active, but at a slightly higher concentration of 15 μM, reducing the numbers of viable trophozoites by 98%, inhibiting cyst formation by 84% and preventing the emergence of trophozoites from cysts by 99%. At their greatest anti-amoeba concentrations, PHA 10 gave only 8% haemolysis at 15 μM while PHA 30 gave <40 % haemolysis at 3.75 μM. Polyhomoarginine 10 showed excellent anti-amoebic activity against both forms of Acanthamoeba castellanii and was non-toxic at its most active concentrations. This implies that polyhomoarginines can be developed into a potential therapeutic agent for Acanthamoeba keratitis. However, there is a need to carry out further pre-clinical and then in vivo experiments in the AK animal model.

Indexed as

Acanthamoebaantimicrobial peptidesarginine peptidesfree-living amoebapolyhomoarginine

Identifiers

PMID36552236
PMCPMC9774714

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.